NCT06134843View on ClinicalTrials.gov

Study to Assess the Safety and Efficacy of DERMASEAL for the Treatment of Split-Thickness Skin Graft Donor Site Wounds

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

April 15, 2025

Conditions

Skin Graft Complications

Interventions

COMBINATION_PRODUCT

DERMASEAL

plasma film containing metallic silver microparticles and fibrin

All Listed Sponsors

collaborator

Vitruvian Medical Devices, Inc.

INDUSTRY

lead

Hobart W. Harris

INDUSTRY

NCT06134843 - Study to Assess the Safety and Efficacy of DERMASEAL for the Treatment of Split-Thickness Skin Graft Donor Site Wounds | Biotech Hunter | Biotech Hunter